비교리스트

 카트 문의
시장보고서
상품코드
1360071

중남미의 바이오의약품 시장 예측(-2028년) : 지역별 분석 - 제품 유형별, 용도별

South & Central America Biopharmaceuticals Market Forecast to 2028 -Regional Analysis - by Product Type and Application
발행일: | 리서치사: The Insight Partners | 페이지 정보: 영문 220 Pages | 배송안내 : 즉시배송

    
    
    



※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

중남미의 바이오의약품 시장은 2022년에 178억 5,000만 달러를 기록했으며, 2028년에는 349억 7,000만 달러에 달할 것으로 예측되고 있습니다. 2022-2028년의 CAGR은 11.9%로 추정됩니다.

중남미 바이오의약품 수탁제조이 중남미 바이오의약품 시장을 주도

의약품 수탁제조기관(CMO)은 제약회사에 많은 이점을 가져다주는데, CMO에 업무를 아웃소싱하면 제조시설 운영 및 유지에 필요한 투자를 줄일 수 있으며, 순현금흐름을 개선할 수 있습니다. 아웃소싱은 비용이 저렴하고 제조 공정의 효율성을 높입니다. 또한 바이오제약 기업은 자원을 다른 중요한 분야에 투입할 수 있습니다. 많은 바이오 제약 회사들이 R&D와 같은 핵심 역량에 집중하고 있으며, 그 결과 자체 제조 역량을 매각하고 CMO에 대한 의존도를 높이고 있으며, CMO는 제약 회사가 공급 부족의 위험을 줄이기 위해 다중 거점 공급 전략과 백업 역량을 통해 추가 역량을 제공하고 있습니다, 추가 거점을 제공합니다. 예를 들어 2022년 3월 바이오엔텍SE는 리제네론과 파트너십을 맺고 진행성 비소세포폐암(NSCLC) 치료를 위해 PD-1 억제제인 리브타요(cemiplimab)와 병용하는 픽스백 후보물질 BNT116을 발전시키기 위해 제휴를 맺었습니다. 이번 제휴를 통해 양사는 진행성 비소세포폐암 환자를 대상으로 병용요법을 평가하기 위한 임상시험을 공동으로 진행하게 됩니다. 이처럼 바이오의약품 수탁제조의 인기가 높아짐에 따라 향후 몇 년간 중남미 바이오의약품 시장의 성장을 가속할 것으로 보입니다.

중남미 바이오의약품 시장 개요

중남미 바이오의약품 시장은 브라질, 아르헨티나, 기타 중남미로 구분됩니다. 중남미 영상센터에서는 디지털 엑스레이 촬영이 널리 보급되고 있습니다. 중남미 바이오의약품 시장의 성장 요인으로는 높은 암 발병률, 바이오의약품 기술 혁신의 발전, 암 발병 위험이 높은 노령 인구 증가 향후 개발될 다양한 신약에 대한 조사 연구 등을 꼽을 수 있습니다. 바이오 의약품은 의학 역사상 가장 중요한 기술 혁신 중 하나입니다. 그러나 이러한 획기적인 치료법은 발견과 개발에 많은 투자가 필요하기 때문에 매우 비싸기 때문에 더 저렴한 대체품이 요구되고 있습니다. 중남미는 생물학적 제제, 특히 바이오시밀러에 있으며, 큰 기회입니다. 중남미에서는 바이오시밀러에 대한 지식과 개발 수준이 높기 때문에 국내외 제약회사들이 이 시장에 진출하여 국내외에서 연구, 제조, 상업화를 하는 데 큰 관심을 보이고 있습니다. 생물학적 제제 시장은 주로 새로운 분자의 발견으로 인해 예측 기간 중 급성장할 것으로 예상됩니다. 생물학적 제제 제조에 필요한 첨단 기술과 자원은 소규모 생명공학 기업에게는 높은 진입장벽으로 작용하고 있습니다. 이 때문에 이 지역에서는 대형 다국적 기업이 전체 생물학적 제제 시장을 지배하고 있습니다. 이들 기업은 끊임없이 혁신적인 신제품을 제공함으로써 바이오시밀러 시장에서 우위를 점하기 위해 연구개발에 많은 투자를 하고 있습니다. 중남미 바이오시밀러 시장 진출기업이 직면한 주요 과제는 높은 R&D 비용, 제품의 효능과 안전성을 입증하는 데 필요한 임상시험, 저렴한 가격을 유지해야 한다는 점 등입니다. 중남미에서는 인슐린, 과립구 집락 자극 인자(G-CSF), 에리스로포이에틴, 인간 성장호르몬의 바이오시밀러 제품이 먼저 시장에 등장했습니다. 이후 인터페론이 등장했고, 마지막으로 모노클로널 항체가 등장했습니다. 또한 리툭시맙, 에타너셉, 라코투누맙 등의 제품이 중남미에 진출하면 바이오시밀러 시장은 더욱 확대될 것으로 보입니다. 지역적 확장과 경제 성장을 배경으로 여러 세계 제약사들이 브라질 시장을 선택하고 있습니다. 이들은 바이오시밀러 시장에 능숙하기 때문에 현지 기업만의 빠른 시장 확대에 기여하며 중남미 바이오의약품 시장을 끌어올릴 것으로 보입니다.

중남미 바이오의약품 시장 매출 및 2028년까지의 예측(10억 달러)

중남미 바이오 의약품 시장 세분화

중남미 바이오의약품 시장은 제품 유형, 용도, 국가별로 구분됩니다.

제품 유형별로 중남미 바이오의약품 시장은 모노클로널 항체, 재조합 백신, 재조합 백신, 재조합 성장인자, 정제 단백질, 재조합 단백질, 재조합 호르몬, 재조합 효소, 세포 및 유전자 치료제로 나뉩니다, 2022년에는 모노클로널 항체 분야가 중남미 바이오의약품 시장에서 가장 큰 점유율을 차지할 것으로 예상되며, 세포-유전자치료제, 사이토카인-인터페론-인터루킨, 기타로 구분됩니다.

재조합 백신 분야는 다시 암 백신, 말라리아 백신, 에볼라 백신, B형 간염 백신, 파상풍 백신, 디프테리아 백신, 콜레라 백신, 기타로 나뉩니다. 기존형 백신 분야는 다시 소아마비 백신, 톡스 백신, 기타로 세분화됩니다. 재조합 성장 인자 부문은 다시 에리스로포이에틴, 과립구 콜로니 자극 인자로 세분화됩니다. 정제된 단백질 부문은 백혈병 억제 인자(LIF), P53 단백질, P38 단백질 및 기타로 세분화됩니다. 재조합 단백질 부문은 혈청 알부민, 아밀로이드 단백질, 디펜신, 트랜스페린으로 세분화됩니다. 재조합 호르몬은 재조합 인간 성장호르몬, 재조합 인슐린 및 기타 재조합 호르몬으로 세분화됩니다. 재조합 효소 부문은 다시 엔테로키나제, 시클라제, 카스파제, 카텝신으로 세분화됩니다. 세포 및 유전자 치료 분야는 다시 동종 제품, 자가 제품, 무세포 제품으로 나뉩니다.

용도별로 중남미 바이오의약품 시장은 암, 염증 및 감염, 자가면역질환, 대사질환, 호르몬질환 및 성장장애, 심혈관질환, 신경질환, 기타로 구분되며, 2022년 중남미 바이오의약품 시장에서 암 분야가 가장 큰 점유율을 차지할 것으로 예상됩니다.

국가별로 보면 중남미 바이오 의약품 시장은 브라질, 아르헨티나, 기타 남미로 구분되며, 2022년 브라질이 중남미 바이오 의약품 시장에서 가장 큰 점유율을 차지할 것입니다.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson &Johnson, Lonza Group AG, Thermo Fisher Scientific Inc 등이 중남미 바이오 의약품 시장에서 사업을 운영하는 주요 기업입니다.

목차

제1장 서론

제2장 중남미 바이오의약품 시장 - 요점

제3장 조사 방법

  • 조사 범위
  • 2차 조사
  • 1차 조사

제4장 중남미의 바이오의약품 시장 : 시장 구도

  • 개요
  • 중남미의 PEST 분석
  • 전문가의 견해

제5장 남미·중남미 바이오의약품 시장 : 주요 시장 역학

  • 시장 촉진요인
    • 암 치료제에 대한 응용 확대
    • 희귀질환 치료의 가능성
  • 시장 억제요인
    • 제조 인프라의 고비용
  • 시장 기회
    • 임상시험의 가속
  • 향후 동향
    • 바이오의약품 수탁제조
  • 영향 분석

제6장 바이오의약품 시장 : 중남미 분석

  • 중남미 바이오의약품 시장 매출 예측과 분석

제7장 중남미 바이오의약품 시장 - 제품 유형별 매출과 2028년까지의 예측

  • 개요
  • 바이오의약품 시장의 제품 유형별 매출 점유율(2021년·2028년)
  • 모노클로널 항체
  • 재조합 백신
  • 기존형 백신
  • 재조합 성장요인
  • 정제 단백질
  • 재조합 단백질
  • 재조합 호르몬
  • 재조합 효소
  • 세포 및 유전자 치료
  • 사이토카인/인터페론/인터류킨
  • 기타(mRNA 기반 치료제 등)

제8장 중남미 바이오의약품 시장 분석과 2028년까지의 예측 : 용도별

  • 개요
  • 중남미의 바이오의약품 시장 : 용도별, 2021년·2028년(%)
  • 암영역
  • 염증성 질환 및 감염성 질환
  • 자가면역질환
  • 대사질환
  • 호르몬 장애와 성장 부전
  • 심혈관질환
  • 신경질환
  • 기타 치료 용도

제9장 중남미 바이오의약품 시장 : 매출과 2028년까지의 예측 : 국가별 분석

    • 중남미
      • 브라질
      • 아르헨티나
      • 기타 중남미

제10장 중남미 바이오의약품 시장 : 업계 상황

  • 유기적 성장 전략
  • 무기적 성장 전략

제11장 기업 개요

  • Amgen Inc
  • AbbVie Inc
  • Eli Lilly and Co
  • Bristol-Myers Squibb Co
  • Johnson & Johnson
  • Boehringer Ingelheim International GmbH
  • Thermo Fisher Scientific Inc
  • AGC Biologics AS
  • Lonza Group AG

제12장 부록

KSA 23.10.25

The South & Central America biopharmaceuticals market was valued at US$ 17.85 billion in 2022 and is projected to reach US$ 34.97 billion by 2028. It is estimated to grow at a CAGR of 11.9% from 2022 to 2028.

Contract Manufacturing of Biopharmaceuticals Drives South & Central America Biopharmaceuticals Market

Contract manufacturing organizations (CMOs) bring many benefits to the table for pharmaceutical companies. Outsourcing tasks to CMOs help them reduce investments required for operating and maintaining manufacturing facilities, thereby aiding improvements in the net cash flow. Outsourcing is cheaper and increases the efficiency of manufacturing processes. Also, it allows biopharmaceutical companies to redirect resources to other important areas. Many biopharmaceutical companies are refocusing on their core capabilities, such as research and development, leading to divestments of in-house manufacturing capacities, which subsequently results in an increased dependence on CMOs for manufacturing. CMOs provide additional capacities and offer additional sites for pharmaceutical companies to mitigate the risk of supply shortages through multisite supply strategies and backup capacities. For instance, in March 2022, BioNTech SE announced a collaboration with Regeneron to advance the FixVac candidate BNT116 in combination with Libtayo (cemiplimab), a PD-1 inhibitor for treating advanced non-small cell lung cancer (NSCLC). The collaboration agreement allows the companies to jointly conduct clinical trials to evaluate the combination therapy in different patients suffering from advanced NSCLC. Thus, the increasing popularity of biopharmaceuticals contract manufacturing is likely to catalyze the growth of the South & Central America biopharmaceuticals market in the coming years.

South & Central America Biopharmaceuticals Market Overview

The South & Central America Biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. Digital radiography is becoming more prevalent in imaging centers across South & Central America. The high burden of cancer, ongoing innovations in biopharmaceuticals technologies, increase in the geriatric population that is at a greater risk of cancer, and research studies on various new upcoming medicines are among the factors contributing to the growth of biopharmaceuticals market in South & Central America. Biopharmaceuticals products are among the most important innovations in medical history. However, these breakthrough therapies, which are extremely expensive due to the large investments required for their discovery and development, call for cheaper alternatives. South & Central America provides a great opportunity for biologic medicines, particularly biosimilars. In South & Central America, there is a high level of knowledge and development of biosimilars; hence, there is a great interest in local and foreign pharmaceutical companies to enter the market to research, manufacture, and commercialize locally and internationally. The biologics market is set to grow rapidly over the forecast period, mainly due to the discovery of new molecules. The advanced technology and resources required to manufacture biologics create high barriers to entry for small biotech companies. This explains why large multinational companies dominate the entire biologics market in the region. These companies invest heavily in R&D to stay ahead in the biosimilar market by constantly offering new innovative products. The main challenges faced by participants in the South & Central America biosimilar market are related to the high cost of research and development, the clinical trials required to prove product efficacy and safety, and the need to maintain low-end prices. In South & Central America, the first biosimilar product to appear on the market was insulin: granulocyte colony-stimulating factor (G-CSF), erythropoietin, and human growth hormone. Interferon later came to the region, and finally, monoclonal antibodies. In addition, the market entry of products such as rituximab, etanercep, and racotunumab in South & Central America would expand the market for biosimilars. Several global pharmaceutical companies have chosen the Brazil market due to their geographic expansion and growing economy. Because of their skills in the biosimilars market, they will help expand the market faster with only local companies, thereby boosting the South & Central America biopharmaceuticals market in the region.

South & Central America Biopharmaceuticals Market Revenue and Forecast to 2028 (US$ Billion)

South & Central America biopharmaceuticals market Segmentation

The South & Central America biopharmaceuticals market is segmented into product type, application, and country.

Based on product type, the South & Central America biopharmaceuticals market is segmented into monoclonal antibodies, recombinant vaccines, conventional vaccines, recombinant growth factors, purified proteins, recombinant proteins, recombinant hormones, recombinant enzymes, cell & gene therapies, cytokines/interferon/interleukins, and others. In 2022, the monoclonal antibodies segment held the largest share of the South & Central America biopharmaceuticals market.

The recombinant vaccines segment is further segmented into cancer vaccine, malaria vaccine, Ebola vaccine, hepatitis-B vaccine, tetanus vaccine, diphtheria vaccine, cholera vaccine, and others. The conventional vaccines segment is further segmented into polio vaccine, pox vaccine, and others. The recombinant growth factors segment is further segmented into erythropoietin and granulocyte colony stimulating factor. The purified proteins segment is further segmented into leukemia inhibitory factor (LIF), P53 protein, P38 protein, and others. The recombinant proteins segment is further segmented into serum albumin, amyloid protein, defensin, and transferrin. The recombinant hormones segment is further segmented into recombinant human growth hormones, recombinant insulin, and other recombinant hormones. The recombinant enzymes segment is further segmented into enterokinase, cyclase, caspase, and cathepsin. The cell & gene therapies segment is further segmented into allogenic products, autologous products, and acellular products.

Based on application, the South & Central America biopharmaceuticals market is segmented into oncology, inflammatory & infectious disease, autoimmune disorders, metabolic disorders, hormonal disorders & growth failure, cardiovascular diseases, neurological diseases, and others. In 2022, the oncology segment held the largest share of the South & Central America biopharmaceuticals market.

Based on country, the South & Central America biopharmaceuticals market is segmented into Brazil, Argentina, and the Rest of South & Central America. In 2022, Brazil held the largest share of the South & Central America biopharmaceuticals market.

AbbVie Inc, AGC Biologics AS, Amgen Inc, Boehringer Ingelheim International GmbH, Bristol-Myers Squibb Co, Eli Lilly and Co, Johnson & Johnson, Lonza Group AG, and Thermo Fisher Scientific Inc are among the leading companies operating in the South & Central America biopharmaceuticals market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the South & Central America biopharmaceutical market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the South & Central America biopharmaceutical market, thereby allowing players across the value chain to develop effective long-term strategies
  • develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth South & Central America market trends and outlook coupled with the factors driving the biopharmaceutical market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 South & Central America Biopharmaceuticals Market - by Product Type
    • 1.3.2 South & Central America Biopharmaceuticals Market - by Application
    • 1.3.3 South & Central America Biopharmaceuticals Market - by Country

2. South & Central America Biopharmaceuticals Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. South & Central America Biopharmaceuticals Market - Market Landscape

  • 4.1 Overview
  • 4.2 South & Central America PEST Analysis
  • 4.3 Expert's Opinion

5. South & Central America Biopharmaceuticals Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Rising Application in Cancer Therapeutics
    • 5.1.2 Potential to Treat Rare Diseases
  • 5.2 Market Restraints
    • 5.2.1 High Cost of Manufacturing Infrastructure
  • 5.3 Market Opportunities
    • 5.3.1 Accelerated Clinical Trials
  • 5.4 Future Trends
    • 5.4.1 Contract Manufacturing of Biopharmaceuticals
  • 5.5 Impact Analysis

6. Biopharmaceuticals Market - South & Central America Analysis

  • 6.1 South & Central America Biopharmaceuticals Market Revenue Forecast and Analysis

7. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - by Product Type

  • 7.1 Overview
  • 7.2 Biopharmaceuticals Market Revenue Share, by Product Type 2021 & 2028 (%)
  • 7.3 Monoclonal Antibodies
    • 7.3.1 Overview
    • 7.3.2 Monoclonal Antibodies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Recombinant Vaccines
    • 7.4.1 Overview
    • 7.4.2 Recombinant Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.1 Cancer Vaccine
        • 7.4.2.1.1 Overview
        • 7.4.2.1.2 Cancer Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.2 Malaria Vaccine
        • 7.4.2.2.1 Overview
        • 7.4.2.2.2 Malaria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.3 Ebola Vaccine
        • 7.4.2.3.1 Overview
        • 7.4.2.3.2 Ebola Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.4 Hepatitis-B Vaccine
        • 7.4.2.4.1 Overview
        • 7.4.2.4.2 Hepatitis-B Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.5 Tetanus Vaccine
        • 7.4.2.5.1 Overview
        • 7.4.2.5.2 Tetanus Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.6 Diphtheria Vaccine
        • 7.4.2.6.1 Overview
        • 7.4.2.6.2 Diphtheria Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.7 Cholera Vaccine
        • 7.4.2.7.1 Overview
        • 7.4.2.7.2 Cholera Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.4.2.8 Others
        • 7.4.2.8.1 Overview
        • 7.4.2.8.2 Others: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Conventional Vaccines
    • 7.5.1 Overview
    • 7.5.2 Conventional Vaccines: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.1 Polio Vaccine
        • 7.5.2.1.1 Overview
        • 7.5.2.1.2 Polio Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.2 Pox Vaccine
        • 7.5.2.2.1 Overview
        • 7.5.2.2.2 Pox Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.5.2.3 Other Conventional Vaccine
        • 7.5.2.3.1 Overview
        • 7.5.2.3.2 Other Conventional Vaccine: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Recombinant Growth Factors
    • 7.6.1 Overview
    • 7.6.2 Recombinant Growth Factors: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.1 Erythropoietin
        • 7.6.2.1.1 Overview
        • 7.6.2.1.2 Erythropoietin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.6.2.2 Granulocyte Colony Stimulating Factor
        • 7.6.2.2.1 Overview
        • 7.6.2.2.2 Granulocyte Colony Stimulating Factor: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.7 Purified Proteins
    • 7.7.1 Overview
    • 7.7.2 Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.1 Leukemia Inhibitory Factor (LIF)
        • 7.7.2.1.1 Overview
        • 7.7.2.1.2 Leukemia Inhibitory Factor (LIF): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.2 P53 Protein
        • 7.7.2.2.1 Overview
        • 7.7.2.2.2 P53 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.3 P38 Protein
        • 7.7.2.3.1 Overview
        • 7.7.2.3.2 P38 Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.7.2.4 Other Purified Proteins
        • 7.7.2.4.1 Overview
        • 7.7.2.4.2 Other Purified Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.8 Recombinant Proteins
    • 7.8.1 Overview
    • 7.8.2 Recombinant Proteins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.1 Serum Albumin
        • 7.8.2.1.1 Overview
        • 7.8.2.1.2 Serum Albumin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.2 Amyloid Protein
        • 7.8.2.2.1 Overview
        • 7.8.2.2.2 Amyloid Protein: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.3 Defensin
        • 7.8.2.3.1 Overview
        • 7.8.2.3.2 Defensin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.8.2.4 Transferrin
        • 7.8.2.4.1 Overview
        • 7.8.2.4.2 Transferrin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.9 Recombinant Hormones
    • 7.9.1 Overview
    • 7.9.2 Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.1 Recombinant Human Growth Hormones
        • 7.9.2.1.1 Overview
        • 7.9.2.1.2 Recombinant Human Growth Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.2 Recombinant Insulin
        • 7.9.2.2.1 Overview
        • 7.9.2.2.2 Recombinant Insulin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.9.2.3 Other Recombinant Hormones
        • 7.9.2.3.1 Overview
        • 7.9.2.3.2 Other Recombinant Hormones: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.10 Recombinant Enzymes
    • 7.10.1 Overview
    • 7.10.2 Recombinant Enzymes: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.1 Enterokinase
        • 7.10.2.1.1 Overview
        • 7.10.2.1.2 Enterokinase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.2 Cyclase
        • 7.10.2.2.1 Overview
        • 7.10.2.2.2 Cyclase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.3 Caspase
        • 7.10.2.3.1 Overview
        • 7.10.2.3.2 Caspase: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.10.2.4 Cathepsin
        • 7.10.2.4.1 Overview
        • 7.10.2.4.2 Cathepsin: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.11 Cell and Gene Therapies
    • 7.11.1 Overview
    • 7.11.2 Cell and Gene Therapies: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.1 Allogenic Products
        • 7.11.2.1.1 Overview
        • 7.11.2.1.2 Allogenic Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.2 Autologous Products
        • 7.11.2.2.1 Overview
        • 7.11.2.2.2 Autologous Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
      • 7.11.2.3 Acellular Products
        • 7.11.2.3.1 Overview
        • 7.11.2.3.2 Acellular Products: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.12 Cytokines/Interferon/Interleukins
    • 7.12.1 Overview
    • 7.12.2 Cytokines/Interferon/Interleukins: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.13 Others (mRNA Based Therapeutics, etc.)
    • 7.13.1 Overview
    • 7.13.2 Others (mRNA Based Therapeutics, etc.): South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

8. South & Central America Biopharmaceuticals Market Analysis and Forecasts to 2028 - by Application

  • 8.1 Overview
  • 8.2 South & Central America Biopharmaceuticals Market, by Application 2021 & 2028 (%)
  • 8.3 Oncology
    • 8.3.1 Overview
    • 8.3.2 Oncology: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Inflammatory and Infectious Diseases
    • 8.4.1 Overview
    • 8.4.2 Inflammatory and Infectious Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.5 Autoimmune Disorders
    • 8.5.1 Overview
    • 8.5.2 Autoimmune Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.6 Metabolic Disorders
    • 8.6.1 Overview
    • 8.6.2 Metabolic Disorders: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.7 Hormonal Disorders and Growth Failure
    • 8.7.1 Overview
    • 8.7.2 Hormonal Disorders and Growth Failure: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.8 Cardiovascular Diseases
    • 8.8.1 Overview
    • 8.8.2 Cardiovascular Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.9 Neurological Diseases
    • 8.9.1 Overview
    • 8.9.2 Neurological Diseases: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.10 Other Therapeutic Applications
    • 8.10.1 Overview
    • 8.10.2 Other Therapeutic Applications: South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)

9. South & Central America Biopharmaceuticals Market - Revenue and Forecast to 2028 - Country Analysis

  • 9.1 Overview
    • 9.1.1 South & Central America: Biopharmaceuticals Market, by Country, 2021 & 2028 (%)
      • 9.1.1.1 Brazil: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.1.1 Brazil: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.1.1.1 Brazil: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.2 Brazil: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.1.1.3 Brazil: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.1.1.4 Brazil: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.5 Brazil: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.1.1.6 Brazil: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.1.1.7 Brazil: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.1.1.8 Brazil: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.1.2 Brazil: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.2 Argentina: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.2.1 Argentina: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.2.1.1 Argentina: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.2 Argentina: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.2.1.3 Argentina: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.2.1.4 Argentina: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.5 Argentina: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.2.1.6 Argentina: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.2.1.7 Argentina: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.2.1.8 Argentina: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.2.2 Argentina: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)
      • 9.1.1.3 Rest of South & Central America: Biopharmaceuticals Market - Revenue and Forecast to 2028 (US$ Million)
        • 9.1.1.3.1 Rest of South & Central America: Biopharmaceuticals Market, by Product Type, 2019-2028 (US$ Million)
        • 9.1.1.3.1.1 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.2 Rest of South & Central America: Biopharmaceuticals Market, by Conventional Vaccines, 2019-2028 (US$ Million)
        • 9.1.1.3.1.3 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Growth Factors, 2019-2028 (US$ Million)
        • 9.1.1.3.1.4 Rest of South & Central America: Biopharmaceuticals Market, by Purified Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.5 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Proteins, 2019-2028 (US$ Million)
        • 9.1.1.3.1.6 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Hormones, 2019-2028 (US$ Million)
        • 9.1.1.3.1.7 Rest of South & Central America: Biopharmaceuticals Market, by Recombinant Enzymes, 2019-2028 (US$ Million)
        • 9.1.1.3.1.8 Rest of South & Central America: Biopharmaceuticals Market, by Cell & Gene Therapies, 2019-2028 (US$ Million)
        • 9.1.1.3.2 Rest of South & Central America: Biopharmaceuticals Market, by Application, 2019-2028 (US$ Million)

10. South & Central America Biopharmaceuticals Market - Industry Landscape

  • 10.1 Overview
  • 10.2 Organic Growth Strategies
    • 10.2.1 Overview
  • 10.3 Inorganic Growth Strategies
    • 10.3.1 Overview

11. Company Profiles

  • 11.1 Amgen Inc
    • 11.1.1 Key Facts
    • 11.1.2 Business Description
    • 11.1.3 Products and Services
    • 11.1.4 Financial Overview
    • 11.1.5 SWOT Analysis
    • 11.1.6 Key Developments
  • 11.2 AbbVie Inc
    • 11.2.1 Key Facts
    • 11.2.2 Business Description
    • 11.2.3 Products and Services
    • 11.2.4 Financial Overview
    • 11.2.5 SWOT Analysis
    • 11.2.6 Key Developments
  • 11.3 Eli Lilly and Co
    • 11.3.1 Key Facts
    • 11.3.2 Business Description
    • 11.3.3 Products and Services
    • 11.3.4 Financial Overview
    • 11.3.5 SWOT Analysis
    • 11.3.6 Key Developments
  • 11.4 Bristol-Myers Squibb Co
    • 11.4.1 Key Facts
    • 11.4.2 Business Description
    • 11.4.3 Products and Services
    • 11.4.4 Financial Overview
    • 11.4.5 SWOT Analysis
    • 11.4.6 Key Developments
  • 11.5 Johnson & Johnson
    • 11.5.1 Key Facts
    • 11.5.2 Business Description
    • 11.5.3 Products and Services
    • 11.5.4 Financial Overview
    • 11.5.5 SWOT Analysis
    • 11.5.6 Key Developments
  • 11.6 Boehringer Ingelheim International GmbH
    • 11.6.1 Key Facts
    • 11.6.2 Business Description
    • 11.6.3 Products and Services
    • 11.6.4 Financial Overview
    • 11.6.5 SWOT Analysis
    • 11.6.6 Key Developments
  • 11.7 Thermo Fisher Scientific Inc
    • 11.7.1 Key Facts
    • 11.7.2 Business Description
    • 11.7.3 Products and Services
    • 11.7.4 Financial Overview
    • 11.7.5 SWOT Analysis
    • 11.7.6 Key Developments
  • 11.8 AGC Biologics AS
    • 11.8.1 Key Facts
    • 11.8.2 Business Description
    • 11.8.3 Products and Services
    • 11.8.4 Financial Overview
    • 11.8.5 SWOT Analysis
    • 11.8.6 Key Developments
  • 11.9 Lonza Group AG
    • 11.9.1 Key Facts
    • 11.9.2 Business Description
    • 11.9.3 Products and Services
    • 11.9.4 Financial Overview
    • 11.9.5 SWOT Analysis
    • 11.9.6 Key Developments

12. Appendix

  • 12.1 About The Insight Partners
  • 12.2 Glossary of Terms
비교리스트
0 건의 상품을 선택 중
상품 비교하기
전체삭제